Comparative Pharmacology
Head-to-head clinical analysis: LAMISIL versus TIOCONAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMISIL versus TIOCONAZOLE.
LAMISIL vs TIOCONAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Allylamine antifungal that inhibits squalene epoxidase, an enzyme in the ergosterol biosynthesis pathway, leading to accumulation of squalene and disruption of fungal cell membrane function.
Inhibition of fungal CYP450-dependent 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
250 mg orally once daily for 2-6 weeks for dermatophyte infections; 250 mg orally once daily for 12 weeks for onychomycosis.
Topical: Apply 1% cream, lotion, or solution to affected area twice daily for 2-4 weeks. Vaginal: Insert 1 applicatorful of 6.5% ointment intravaginally at bedtime as a single dose.
None Documented
None Documented
Clinical Note
moderateTioconazole + Tranilast
"The risk or severity of adverse effects can be increased when Tioconazole is combined with Tranilast."
Clinical Note
moderateTioconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Tioconazole is combined with Tolfenamic acid."
Clinical Note
moderateTioconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Tioconazole is combined with Nimesulide."
Clinical Note
moderateTioconazole + Risedronic acid
Terminal elimination half-life is approximately 17-24 hours in healthy adults. However, it can prolong to about 36-40 hours in patients with renal or hepatic impairment. The prolonged half-life allows for once-daily dosing. Due to extensive tissue distribution, the functional half-life (terminal phase from tissues) may be longer.
Terminal elimination half-life is approximately 24–30 hours after topical application, reflecting slow systemic clearance of absorbed fraction.
Approximately 70% of the administered dose is excreted in the urine as metabolites, with less than 5% as unchanged drug. About 20% is eliminated via feces. Terbinafine undergoes extensive hepatic metabolism; renal elimination of metabolites is the primary route.
Primarily fecal (minimally absorbed; <5% absorbed dose excreted renally as metabolites); topically applied tioconazole is largely unabsorbed.
Category C
Category A/B
Antifungal
Antifungal
"The risk or severity of adverse effects can be increased when Tioconazole is combined with Risedronic acid."